Drug intelligence / Profile preview

WT-5860

Development stage: Preclinical
Lead developer: WARF Therapeutics
Modality: Small Molecules

Overview

WT-5860 is a small-molecule ligand developed by WARF Therapeutics that targets the prostate-specific membrane antigen (PSMA). It is designed for use in imaging and/or targeted therapy for prostate cancer. PSMA is highly overexpressed in prostate cancer cells, making it an ideal target for delivering diagnostic or therapeutic agents. WT-5860 is currently in the preclinical stage, specifically in Stage 4 Lead Optimization, where it is being evaluated for its binding affinity and potential as a delivery vehicle for therapeutic or diagnostic payloads.

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on WT-5860.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WT-5860.

Explore the full profile